Project Grant R21CA288922
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$387K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $299,995 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, FL. The grant will fund a project to develop and validate computed tomography (CT) image-based biomarkers that can predict survival outcomes for patients with high-grade serous ovarian carcinoma (HGSOC), the most common and deadly type of epithelial ovarian cancer. The...
This federal Project Grant award of $221,456.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop and optimize a novel approach for enriching microbes from clinical cancer samples to enable deep metaproteomic analysis. The research team, led by the Regents of the University of Minnesota, will pursue two specific aims: 1) Optimize and evaluate the CS-BONCAT (bio-orthogonal non-canonical amino acid tagging) method in samples of known...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $162,486 to The Johns Hopkins University from January 2025 to October 2027 to advance non-invasive screening and characterization of ovarian cancers. The project aims to: Develop novel bioinformatics approaches to study repeat elements in cell-free DNA, which could elucidate the role of the "dark genome" in ovarian tumorigenesis. Create sensitive and specific cell-free DNA liquid...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $159,803 to the Regents of the University of Michigan to incorporate emerging genomic, transcriptomic, epigenomic, and proteomic technologies for the analysis of advanced, rare, and pediatric cancers. The project aims to translate these new analytical approaches into clinically actionable information through the development of reportable test results in the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $212,013 to the Regents of the University of Minnesota to characterize the metabolic landscape of ARID1A-mutated ovarian clear cell carcinoma (OCCC). The research aims to identify unique proteomic and functional mitochondrial signatures associated with ARID1A deficiency in OCCC tumors, as well as perform a genetic screen of the mitochondrial electron transport chain in...
The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...